Ascendiant Capital Markets Comments on NRXP Q3 Earnings

Key Points

• Ascendiant Capital Markets lowered its earnings forecasts for NRx Pharmaceuticals, projecting a Q3 2026 loss of $0.15 per share versus a prior $0.08 loss estimate and cutting its FY2026 forecast to a $0.80 loss per share.
• Analyst sentiment remains mixed: five analysts rate NRXP a Buy and two rate it a Sell, resulting in a consensus rating of Hold and an average price target of $34.50.
• NRXP shares opened at $2.87 and recently declined 1.0%; the company’s latest quarterly results missed expectations, reporting a $0.44-per-share loss and $1.10 million in revenue versus consensus estimates of a $0.11 loss and $1.33 million in revenue.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Free Report) - Equities researchers at Ascendiant Capital Markets dropped their Q3 2026 EPS estimates for NRx Pharmaceuticals in a research note issued on Wednesday, September 30th. Ascendiant Capital Markets analyst E. Woo now forecasts that the company will earn ($0.15) per share for the quarter, down from their previous estimate of ($0.08). The consensus estimate for NRx Pharmaceuticals' current full-year earnings is ($0.36) per share. Ascendiant Capital Markets also issued estimates for NRx Pharmaceuticals' Q4 2026 earnings at ($0.17) EPS, FY2026 earnings at ($0.80) EPS, Q1 2027 earnings at ($0.17) EPS, Q2 2027 earnings at ($0.13) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at $0.05 EPS and FY2027 earnings at ($0.35) EPS.

Several other equities analysts have also recently weighed in on the stock. BTIG Research reaffirmed a "buy" rating and set a $10.00 target price on shares of NRx Pharmaceuticals in a research note on Monday, September 14th. UBS Group restated a "buy" rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 26th. Wall Street Zen downgraded NRx Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Saturday, August 15th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 5th. Finally, HC Wainwright reiterated a "buy" rating on shares of NRx Pharmaceuticals in a research report on Tuesday, August 25th. Five investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $34.50.

NRx Pharmaceuticals Stock Down 1.0%

Shares of NRXP opened at $2.87 on Tuesday. NRx Pharmaceuticals has a 52 week low of $1.62 and a 52 week high of $5.05. The stock has a market cap of $124.27 million, a price-to-earnings ratio of -5.22 and a beta of 2.07. The business has a 50-day simple moving average of $3.31 and a two-hundred day simple moving average of $3.32.

NRx Pharmaceuticals (NASDAQ:NRXP - Get Free Report) last announced its earnings results on Friday, August 14th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.33). The company had revenue of $1.10 million during the quarter, compared to the consensus estimate of $1.33 million.

Hedge Funds Weigh In On NRx Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. AdvisorShares Investments LLC boosted its stake in NRx Pharmaceuticals by 28.2% in the 1st quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company's stock worth $896,000 after purchasing an additional 92,463 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in shares of NRx Pharmaceuticals during the second quarter worth $54,000. Finally, Ethos Financial Group LLC grew its holdings in shares of NRx Pharmaceuticals by 33.6% during the first quarter. Ethos Financial Group LLC now owns 15,900 shares of the company's stock valued at $34,000 after buying an additional 4,000 shares during the last quarter. 4.27% of the stock is owned by hedge funds and other institutional investors.

NRx Pharmaceuticals News Roundup

Here are the key news stories impacting NRx Pharmaceuticals this week:

• Positive Sentiment: NRx Pharmaceuticals secured a DARPA contract and an $11.2 million award to support a clinical trial of its depression treatment. The government-backed funding could strengthen the company’s cash position and advance development of its lead program while reducing near-term financing needs. NRx secures DARPA contract for depression trial and $11.2 million award
• Neutral Sentiment: A separate report compared AstraZeneca and NRx Pharmaceuticals, but provided no clear new operational or financial catalyst for NRXP. AstraZeneca and NRx Pharmaceuticals head-to-head review
• Negative Sentiment: Ascendiant Capital Markets cut its NRx Pharmaceuticals EPS forecast across multiple periods. Its FY2026 estimate fell to a loss of $0.80 per share from a loss of $0.36, while its FY2027 forecast moved to a loss of $0.35 from projected earnings of $0.50. Quarterly estimates were also reduced, including Q3 2026 to a $0.15 loss and Q4 2026 to a $0.17 loss. The revisions suggest weaker-than-expected profitability and could weigh on the stock, which already has a negative earnings profile.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc NASDAQ: NRXP is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders, with an emphasis on depression, suicidal ideation and other serious neuropsychiatric conditions. The company's programs are investigational and are intended to address areas where available therapies may have limitations.

NRx's lead program is NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone being developed for conditions including bipolar depression with acute suicidal ideation or behavior.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.